- Home
- ENX vs PBYI Comparison
ENX vs PBYI Comparison
Compare ENX & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENX
- PBYI
- Stock Information
- Founded
- ENX 2002
- PBYI 2010
- Country
- ENX United States
- PBYI United States
- Employees
- ENX N/A
- PBYI N/A
- Industry
- ENX Finance/Investors Services
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- ENX Finance
- PBYI Health Care
- Exchange
- ENX Nasdaq
- PBYI Nasdaq
- Market Cap
- ENX 167.6M
- PBYI 152.4M
- IPO Year
- ENX N/A
- PBYI N/A
- Fundamental
- Price
- ENX $9.16
- PBYI $3.29
- Analyst Decision
- ENX
- PBYI Strong Buy
- Analyst Count
- ENX 0
- PBYI 1
- Target Price
- ENX N/A
- PBYI $7.00
- AVG Volume (30 Days)
- ENX 25.4K
- PBYI 373.6K
- Earning Date
- ENX 01-01-0001
- PBYI 05-08-2025
- Dividend Yield
- ENX 3.94%
- PBYI N/A
- EPS Growth
- ENX N/A
- PBYI 143.51
- EPS
- ENX 0.16
- PBYI 0.77
- Revenue
- ENX N/A
- PBYI $232,709,000.00
- Revenue This Year
- ENX N/A
- PBYI N/A
- Revenue Next Year
- ENX N/A
- PBYI N/A
- P/E Ratio
- ENX $61.00
- PBYI $4.26
- Revenue Growth
- ENX N/A
- PBYI 2.68
- 52 Week Low
- ENX $7.84
- PBYI $2.23
- 52 Week High
- ENX $10.07
- PBYI $4.13
- Technical
- Relative Strength Index (RSI)
- ENX 37.95
- PBYI 52.53
- Support Level
- ENX $9.18
- PBYI $3.14
- Resistance Level
- ENX $9.37
- PBYI $3.45
- Average True Range (ATR)
- ENX 0.12
- PBYI 0.20
- MACD
- ENX -0.02
- PBYI -0.00
- Stochastic Oscillator
- ENX 5.13
- PBYI 51.79
About ENX Eaton Vance New York Municipal Bond Fund of Beneficial Interest $.01 par value
Eaton Vance New York Municipal Bond Fund is principally engaged in managing investment funds and providing investment management and advisory services to high-net-worth individuals and institutions. It is a non-diversified, closed-end investment company. Its objective is to provide current income exempt from regular federal income tax, including alternative minimum tax, and, in state specific funds, taxes in specified state.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.